HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Michael Burt Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lieberman, M. D. Articles by Burt, M. Search for Related Content PubMed PubMed Citation Articles by Lieberman, M. D. Articles by Burt, M.

J Thorac Cardiovasc Surg 1994;108:1138-1146
© 1994 Mosby, Inc.

GENERAL THORACIC SURGERY

Esophageal carcinomaThe unusual variants

New York, N.Y.

From the Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, N.Y.

Received for publication March 2, 1994. Accepted for publication July 28, 1994. Address for reprints: Michael Burt, MD, PhD, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021.

Abstract

The clinical behavior and response to therapy of rare histologic variants of esophageal carcinoma are unclear. To evaluate the results of therapy in this group the records of 29 patients treated between 1949 and 1991 with primary rare histologic variants of esophageal carcinoma were retrospectively reviewed. This group represented 1.2% of 2454 cases of esophageal carcinoma treated between 1949 and 1991 and included mucoepidermoid (n = 14), small-cell (n = 12), adenoid cystic (n = 2), and carcinosarcoma (n = 1) carcinomas. Treatment for localized disease consisted of esophagectomy in five of seven patients with mucoepidermoid carcinoma, two of six patients with small-cell carcinoma, two of two patients with adenoid cystic carcinoma, and one of one patient with carcinosarcoma. Patients with stage IV mucoepidermoid carcinoma were treated predominately with radiation therapy (5/7). The majority of small cell carcinomas were treated with multiagent chemotherapy (10/12). The 1- and 3-year disease-specific survivals were 54% and 9% for mucoepidermoid carcinoma (median survival, 5 months) and 16% and 0% for small-cell carcinoma (median survival, 7 months), respectively. Patients with stage III mucoepidermoid carcinoma (median survival, 20.5 months) compared with those with stage III small-cell carcinoma (median survival, 6.2 months) had a significantly longer duration of survival (p < 0.05). Distant disease was present in 86% of patients in whom recurrence developed after esophagectomy Esophagectomy is standard therapy for localized carcinomas of the esophagus. Small-cell carcinoma appears to be a more aggressive variant of carcinoma and is most commonly treated with chemotherapy. (J THORAC CARDIOVASC SURG 1994;108:1138-46)

This article has been cited by other articles:

				J.M. Klaase, J.B. F. Hulscher, G.J. A. Offerhaus, F.J. W. ten Kate, H. Obertop, and J.J. B. van Lanschot Surgery for Unusual Histopathologic Variants of Esophageal Neoplasms: A Report of 23 Cases With Emphasis on Histopathologic Characteristics Ann. Surg. Oncol., April 1, 2003; 10(3): 261 - 267. [Abstract] [Full Text] [PDF]

				G. H. Pantvaidya, C.S. Pramesh, M. S. Deshpande, N. A. Jambhekar, S. Sharma, and R. K. Deshpande Small cell carcinoma of the esophagus: the Tata Memorial Hospital experience Ann. Thorac. Surg., December 1, 2002; 74(6): 1924 - 1927. [Abstract] [Full Text] [PDF]